InspireMD (NSPR) Stock Price, News & Analysis

InspireMD, Inc. (NSPR) is a medical device company whose common stock is quoted on the Nasdaq Capital Market under the ticker symbol NSPR, according to its SEC filings. The company is described in public disclosures and press releases as the developer of the CGuard® Prime carotid stent system for the prevention of stroke and as a business that seeks to utilize its proprietary MicroNet™ mesh technology in carotid stenting.

Business focus and core technology

According to multiple company press releases, InspireMD focuses on the development and commercialization of carotid stent systems that incorporate its proprietary MicroNet™ mesh technology. The company states that it aims to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. Its disclosures highlight CGuard® Prime as a carotid stent system designed for the treatment of carotid artery stenosis and for the prevention of stroke.

InspireMD is a United States based medical device company focused on a proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease, with products including the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). The company has generated a majority of its revenue from sales of CGuard EPS.

CGuard® Prime carotid stent system

In recent SEC filings and news releases, InspireMD describes itself as the developer of the CGuard® Prime carotid stent system for the prevention of stroke. A Form 8-K filed on June 24, 2025 reports that the company received FDA premarket approval (PMA) for the CGuard Prime Carotid Stent System in the United States. A later Form 8-K dated July 9, 2025 references a press release announcing the U.S. commercial launch of CGuard® Prime. Subsequent earnings-related news indicates that the company initiated a U.S. commercial launch and completed carotid procedures across hospitals using CGuard Prime.

Company press releases explain that CGuard® Prime is a carotid stent system that incorporates MicroNet™ mesh technology. InspireMD’s descriptions emphasize its goal of providing strong acute performance and durable outcomes in carotid interventions and of supporting a stent-based approach to carotid revascularization.

MicroNet™ mesh platform and product history

Across its communications, InspireMD consistently identifies MicroNet™ mesh as its proprietary technology platform. InspireMD's MicroNet stent platform is for complex vascular and coronary disease, and CGuard EPS and MGuard Prime EPS are products based on this platform. More recent company press releases describe MicroNet™ mesh as the core technology used in CGuard® Prime for carotid stenting, and the company states that it seeks to use this mesh technology to provide stroke-free long-term outcomes.

Clinical evidence and pivotal trials

InspireMD highlights clinical data supporting its carotid stent system. A January 2026 news release reports that results from the company’s C-GUARDIANS pivotal trial of the CGuard® Prime carotid stent system were published in the Journal of the American College of Cardiology (JACC). According to that release, the trial evaluated the safety and efficacy of carotid artery stenting with the company’s MicroNet™ covered stent in patients with asymptomatic carotid stenosis and included both symptomatic and asymptomatic patients with obstructive carotid disease at high risk for complications with carotid endarterectomy.

The C-GUARDIANS trial, as described in the publication summary provided by the company, enrolled patients across sites in the United States and Europe and assessed a composite primary endpoint including death (all-cause mortality), stroke, or myocardial infarction through 30 days, and ipsilateral stroke from 31 to 365 days. InspireMD states that the trial demonstrated low rates of disabling stroke or myocardial infarction through 30 days and low ipsilateral stroke rates through one year, with no unexpected device-related adverse events reported.

In addition to C-GUARDIANS, InspireMD has referenced external clinical evidence that is relevant to carotid artery stenting. A November 2025 press release notes the publication of the NIH-sponsored CREST-2 study in the New England Journal of Medicine and describes the company’s view that CREST-2 data support the role of carotid artery stenting combined with medical therapy for patients with severe asymptomatic carotid stenosis. The company states that these external data, together with its own C-GUARDIANS trial results, support a shift toward an endovascular-first or stent-based approach in certain segments of carotid disease.

Regulatory milestones and U.S. commercialization

InspireMD’s SEC filings and press releases describe a sequence of regulatory and commercial milestones for CGuard® Prime. A Form 8-K dated June 24, 2025 reports that the company received FDA PMA approval of the CGuard Prime Carotid Stent System in the United States on June 23, 2025. A subsequent Form 8-K dated July 9, 2025 references a press release announcing the U.S. commercial launch of CGuard® Prime for the prevention of stroke.

Later financial results releases, referenced in the company’s November 4, 2025 Form 8-K, state that InspireMD initiated its U.S. commercial launch of CGuard Prime and completed carotid procedures across leading hospitals. The company also notes that this initial U.S. commercial activity contributed to revenue and that it has been expanding its U.S. personnel, particularly its commercial team, in connection with the launch.

Geographic activity

InspireMD operates in Italy, Germany, Russia and other countries. More recent company communications describe clinical trial activity across sites in the United States and Europe and reference global experience with implants of its device. For example, a November 2025 press release notes that CGuard has been supported by more than 65,000 global implants and extensive real-world evidence. These statements indicate that InspireMD’s technology has been used in multiple international markets.

Capital markets and corporate governance

InspireMD’s SEC filings provide additional context on its status as a public company and its corporate governance. The company is incorporated in Delaware and files periodic and current reports with the SEC under Commission File Number 001-35731. Its common stock, with a par value of $0.0001 per share, is registered under Section 12(b) of the Securities Exchange Act of 1934 and trades on The Nasdaq Capital Market under the symbol NSPR.

In a Form 8-K filed on July 31, 2025, the company reports that it entered into a securities purchase agreement for a private placement of common stock and pre-funded warrants, with aggregate gross proceeds of approximately $40.1 million before fees and expenses. The same filing also describes the full exercise of a series of warrants, resulting in additional gross proceeds. These disclosures illustrate how InspireMD raises capital to support its operations and commercialization efforts.

Several Form 8-K filings in 2025 describe changes to the company’s board of directors and committee composition, including the appointment of new independent directors and audit committee leadership. The filings state that these directors are considered independent under SEC and Nasdaq rules and provide background on their experience in medical devices and life sciences.

Risk factors and operating considerations

In multiple press releases that include forward-looking statements disclaimers, InspireMD outlines a range of risks and uncertainties associated with its business. These include a history of recurring losses and negative cash flows from operating activities, the need to raise additional capital, uncertainties around clinical development, commercialization and market acceptance of its products, the possibility of negative clinical trial results or product delays, and the need to secure and maintain regulatory approvals.

The company also notes risks related to maintaining compliance with Nasdaq listing standards, dependence on a single manufacturing facility and compliance with manufacturing quality standards, competition in the medical device industry, potential product liability exposure, reimbursement by governmental and third-party payers, intellectual property protection, and the challenges of conducting business in multiple foreign jurisdictions. In some disclosures, InspireMD highlights that security, political and economic instability in the Middle East, including in Israel, could affect its business.

Position within the medical device and carotid intervention space

Based on its own statements, InspireMD positions itself as a developer of carotid stent systems built on proprietary MicroNet™ mesh technology, with a focus on stroke prevention in patients with carotid artery stenosis. The company emphasizes peer-reviewed clinical evidence from its C-GUARDIANS pivotal trial, regulatory approval of CGuard® Prime by the FDA via the PMA pathway, and external data such as CREST-2 as important elements supporting the use of carotid artery stenting.

Through its disclosures, InspireMD presents a strategy centered on advancing a stent-system approach to carotid revascularization and on building physician awareness and adoption of CGuard® Prime. For investors and observers, the company’s SEC filings and press releases provide insight into its technology platform, clinical data, regulatory progress, commercialization steps, capital-raising activities, and the key risks it identifies for its business.